Ovarian Cancer Clinical Trial

Predicting the Risk of Ovarian Cancer Recurrence Using Circulating Tumor DNA to Assess Residual Disease

Summary

Blood samples and Tumor tissue will be collected at certain timepoints and will be tested.

View Full Description

Full Description

Blood samples will be tested by Natera to identify residual tumor DNA for genetic changes in the tumor to potentially improve prediction of long term prognosis and guide treatment options.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Clinical diagnosis of epithelial ovarian cancer stage II-IV

Exclusion Criteria:

Insufficient tumor to perform Signatera testing; Inability to provide consent for the trial

Study is for people with:

Ovarian Cancer

Estimated Enrollment:

45

Study ID:

NCT05212779

Recruitment Status:

Recruiting

Sponsor:

Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

How clear is this clinincal trial information?

Study is for people with:

Ovarian Cancer

Estimated Enrollment:

45

Study ID:

NCT05212779

Recruitment Status:

Recruiting

Sponsor:


Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.